VIYASH

Viyash Scientific share price & financials

Price
₹268.65
Market cap
₹11.2k Cr
Sector
Healthcare
Calls analysed
6
Latest concall · Q1 FY27 · call held 16 Aug 2026

Viyash Scientific Limited Q1 FY27

Revenue from Operations ₹946 cr +20%EBITDA ₹205 cr +59%EBITDA Margin 21.6% Profit After Tax ₹79 cr +115%

What went well

  • Revenue from operations grew 20% year-on-year to ₹946 crores.
  • Adjusted EBITDA increased by 59% year-on-year to ₹205 crores, with EBITDA margin expanding 530 basis points to 21.6%.
  • Profit after tax more than doubled, growing 115% year-on-year to ₹79 crores.

What to watch

  • API revenue was broadly flat quarter-on-quarter due to timing issues related to raw material price volatility and geopolitical uncertainties.
  • Employee Stock Options (ESOPs) resulted in an incremental expense of ₹19 crores for Q1 FY27, impacting PAT.
Read the full call →

What Viyash Scientific Limited does

Viyash Scientific Limited (formerly SeQuent Scientific) is an integrated animal (veterinary) health company that develops, manufactures and markets Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) for livestock, poultry and companion animals, spanning therapeutic areas such as antibiotics, anthelmintics, pain management, nutrition and gut health. It runs manufacturing and R&D sites across India, Spain, Turkey and Brazil, and sells through direct front-end teams and distribution partnerships across Europe, Emerging Markets, USA and India, marketing formulations under its Alivira animal-health brand. In FY25/26 it completed a strategic merger with Viyash Life Sciences Private Limited, combining research, manufacturing and supply-chain capabilities into one integrated global animal-health platform.

Segments

  • Formulations (FDF)
  • APIs
Manufacturing facilities (combined entity)
16
USFDA-approved manufacturing facilities
10
Countries with market presence
150+
Combined API manufacturing capacity
2,400 KL
R&D team size (combined entity)
235+
Commercial APIs
30+
Headquarters Hyderabad, Telangana, India Company website

Guidance record · Q1 FY27

what the last two calls moved 14 tracked 2 delivered 1 missed 11 open
  • Combined EBITDA Margin delivered said Q4 FY25 Promised: Combined entity margin profile closer to 20% by FY27 Q1 FY27: Maintained margin at 21.6% and reiterated guidance of 20-22% range, confirming sustained achievement.
  • Merger Synergies went quiet said Q3 FY26 Promised: INR 50-60 crores in 12-18 months Q1 FY27: No specific update provided on the synergy realization against the revised target of INR 125-150 crores.
  • Combined Top Line at risk said Q4 FY25 Promised: INR 4,000 crore in the next 2 to 2.5 years Q1 FY27: New guidance for FY27 revenue growth is 13-15%. On the FY26 base of INR 3,420 cr, this projects to INR 3,865-3,933 cr, which is below the INR 4,000 cr target. Promise is now at risk.

All 14 tracked — every revision, and every one management stopped mentioning.

Open the guidance ledger

Quarterly results

Q1 FY27: revenue up 7.9%, net profit up 23.5% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue42 338 42 328 340 +710%342 +1%372 +786%354 +8%
EBITDA-2 58 -3 49 52 +2700%70 +21%63 +2200%47 −4%
Net profit4 51 4 17 23 +475%0 −100%36 +800%21 +24%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance +40.6% 1Y

₹200₹250₹300Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Q2 FY26 — 21 Nov 2025Q3 FY26 — 6 Feb 2026Q4 FY26 — 20 May 2026Q1 FY27 — 17 Aug 2026

1Y: ₹183.17 on 10 Sept 2025 → ₹257.6. High ₹294.15 (3 Jul 2026), low ₹179.89 (23 Mar 2026).

How the price took the results

close before → close after

Q1 FY27
−1.4%
16 Aug
Q4 FY26
+10.0%
20 May
Q3 FY26
−3.5%
6 Feb
Q2 FY26
−0.4%
21 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Financials, as filed

Revenue grew 186.8% a year over 2 years, FY24 to FY26. Operating margin widened to 16.9%.

Year endingFY24FY25FY26
Revenue₹168 Cr₹480 Cr₹1.4k Cr
Operating profit₹-27 Cr₹51 Cr₹234 Cr
Operating margin-16.1%10.6%16.9%
Interest₹4 Cr₹9 Cr₹17 Cr
Depreciation₹8 Cr₹38 Cr₹124 Cr
Net profit₹1 Cr₹63 Cr₹76 Cr
Net margin0.6%13.1%5.5%
Cash from operations₹-27 Cr₹188 Cr₹119 Cr
Free cash flow₹-12 Cr₹131 Cr₹50 Cr
ROCE1.0%7.0%6.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹50 Cr₹50 Cr₹50 Cr₹50 Cr₹50 Cr₹87 Cr
Reserves₹980 Cr₹991 Cr₹1.0k Cr₹1.0k Cr₹759 Cr₹3.1k Cr
Borrowings₹6 Cr₹17 Cr₹20 Cr₹47 Cr₹490 Cr₹33 Cr
Other liabilities₹67 Cr₹66 Cr₹44 Cr₹54 Cr₹427 Cr₹433 Cr
Total liabilities₹1.1k Cr₹1.1k Cr₹1.1k Cr₹1.2k Cr₹1.7k Cr₹3.7k Cr
Fixed assets₹66 Cr₹67 Cr₹57 Cr₹43 Cr₹628 Cr₹1.2k Cr
Capital work in progress₹4 Cr₹1 Cr₹2 Cr₹5 Cr₹5 Cr₹55 Cr
Investments₹685 Cr₹659 Cr₹633 Cr₹640 Cr₹0 Cr₹977 Cr
Other assets₹347 Cr₹397 Cr₹431 Cr₹500 Cr₹1.1k Cr₹1.5k Cr
Total assets₹1.1k Cr₹1.1k Cr₹1.1k Cr₹1.2k Cr₹1.7k Cr₹3.7k Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, DIIs trimmed −9.22 pp while promoters added +8.70 pp. The shareholder count shrank 13% to 1,28,367.

Promoters
61.3%
FIIs
4.5%
DIIs
3.8%
Public
30.3%
Others
0.1%

Since Jun 2025

  • DIIs −9.22 pp
  • Promoters +8.70 pp
  • Public +2.24 pp

How it drifted, 12 quarters

Over this window promoters went from 52.8% to 61.3% — +8.5 pp.

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 52.8%, FIIs 6.0%, DIIs 3.2%, Public 37.6%, Others 0.4%.Dec '23: Promoters 52.8%, FIIs 6.1%, DIIs 7.2%, Public 33.7%, Others 0.2%.Mar '24: Promoters 52.8%, FIIs 6.2%, DIIs 7.6%, Public 33.3%, Others 0.2%.Jun '24: Promoters 52.8%, FIIs 5.7%, DIIs 8.1%, Public 33.3%, Others 0.2%.Sep '24: Promoters 52.8%, FIIs 6.5%, DIIs 10.0%, Public 30.6%, Others 0.2%.Dec '24: Promoters 52.6%, FIIs 6.1%, DIIs 12.0%, Public 29.1%, Others 0.2%.Mar '25: Promoters 52.6%, FIIs 6.0%, DIIs 12.8%, Public 28.4%, Others 0.2%.Jun '25: Promoters 52.6%, FIIs 6.2%, DIIs 13.0%, Public 28.1%, Others 0.2%.Sep '25: Promoters 52.3%, FIIs 5.9%, DIIs 12.9%, Public 28.7%, Others 0.2%.Dec '25: Promoters 61.4%, FIIs 3.2%, DIIs 7.4%, Public 28.0%, Others 0.1%.Mar '26: Promoters 61.3%, FIIs 2.9%, DIIs 8.0%, Public 27.7%, Others 0.1%.Jun '26: Promoters 61.3%, FIIs 4.5%, DIIs 3.8%, Public 30.3%, Others 0.1%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Viyash Scientific Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Ca Hull Investments 31.17%unchanged
Ca Harbor Investments 30.14%unchanged
Haribabu Bodepudi 2.77%unchanged
Quant Mutual Fund - Quant Small Cap Fund Mutual fund2.58%newly disclosed
Kalidindi Srihari Raju 2.35%−0.14 pp
Narasimha Reddy Duthala 1.27%unchanged
Quant Mutual Fund - Quant Manufacturing Fund Mutual fund—off the list

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

All earnings calls (6)

Read the Q1 FY27 call →

Learn to analyse Viyash Scientific Limited

Guides on how to read this kind of business and the numbers that matter.